



Medicines & Healthcare products Regulatory Agency

13 August 2026

Dear colleagues

I am pleased to introduce the [MHRA's first quarterly Results and Forecast update](#).

Earlier this year, we published our [2025–26; 2026–27 Results and Forecast](#), bringing together our performance and priorities in a more transparent and accessible way.

This quarterly update and accompanying Quarterly Performance and Forecast report builds on that approach, giving you a regular overview of how we are performing, what we have delivered over the last three months, and where our focus lies for the quarter ahead.

The first quarter of 2026–27 shows strong and consistent delivery across our core regulatory services. We achieved 100% on-time performance for national medicines licence applications and vaccine and blood product certification, while maintaining 98–99% performance across key licensing, variation and authorisation activities.

We have also continued to improve the service we provide to innovators. Scientific advice performance increased to 98% delivered on time, with 91% of advice recipients reporting satisfaction both with the quality of advice received and their overall experience of working with the MHRA. We have also taken on your feedback and will now be reporting end-to-end scientific advice times to ensure that you can plan scientific advice in product development.

Our quarterly performance report introduces more transparency about our performance, including minimum and maximum timelines across key regulatory services. It is designed to give you greater confidence and predictability when choosing to develop, test and launch innovative products in the UK.

Over the last year, with the increasing confidence of our predictability, we are seeing increases in demand on our services, which is very encouraging. It does present the challenge where we are continuing to ask for increased visibility of pipelines and forecasting to enable appropriate delivery of our service.

Alongside our core performance, in the past quarter, we implemented the most significant reforms to UK clinical trial regulation in a generation, progressed major medical device reforms and strengthened international and national regulatory partnerships, including deeper cooperation with the US FDA, and with Scotland, Wales, and Northern Ireland. We also continued to support the development and availability of both innovative medicines and technologies and established products, including generics.

Looking ahead, quarter two will be an important period for the MHRA. We will publish our MHRA2030 Strategy, which will set out our five-year vision for a modern, responsive regulator that protects patients while supporting innovation and growth. We also look forward to the recommendations of the independent National Commission into the Regulation of AI in Healthcare, and to applying these recommendations in setting the framework for a proportionate and future-ready regulatory approach to AI-enabled healthcare in the UK.

We will also launch a consultation on reforms to MHRA fees to help ensure a sustainable regulatory service that continues to meet the needs of patients and innovators. We will continue to advance innovative routes to market, including the new NICE-MHRA aligned pathway, the Innovative Licensing and Access Pathway (ILAP), and the future regulatory framework for rare disease therapies, following our recent public consultation. We will also publish the Government response to our recent consultation on the indefinite recognition of CE-marked medical devices.

Finally, we look forward to meeting many of you at the MHRA-DIA Global Annual Summit on 16-17 November 2026, where we will share more on our priorities for innovation, international collaboration, regulatory science and the delivery of the MHRA2030 Strategy. [Registration for the event at Senate House, London, is now open.](#)

I hope our new quarterly update gives you a clearer understanding of both our performance and our priorities. We remain committed to being a regulator that is rigorous, responsive and transparent in how we operate.

You can read the Quarterly update online: <https://www.gov.uk/government/publications/mhra-quarterly-results-and-forecast-2026-to-2027>

Julian Beach

Executive Director of Healthcare Quality and Access and Chair of the MHRA's Data and Performance Management Committee

Medicines and Healthcare products Regulatory Agency (MHRA)